NUVL
Nuvalent, Inc.
Price Chart
Latest Quote
$123.44
+0.02 (+0.02%)
Current Price
| Previous Close | $123.42 |
| Open | $123.49 |
| Day High | $123.52 |
| Day Low | $123.41 |
| Volume | 1,236,814 |
Stock Information
| Shares Outstanding | 73.69M |
| Cash Equivalents | $1.29B |
| Net Income | $-450.07M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $9.77B |
| EPS (TTM) | $-6.06 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.46B |
| Income | $-450.07M |
| Book/sh | $14.89 |
| Cash/sh | $17.47 |
| Employees | 234 |
Financial Ratios
| Quick Ratio | 15.88 |
| Current Ratio | 16.14 |
Returns & Margins
| ROA | -22.51% |
| ROE | -41.19% |
Ownership
| Insider Ownership | 2.78% |
| Institutional Ownership | 113.09% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -29.88 |
| P/B | 8.29 |
Analyst Data
| Recommendation | hold |
| Target Price | $128.12 |
Technical Indicators
| SMA20 | $110.68 |
| SMA50 | $106.43 |
| SMA200 | $100.11 |
| RSI | 84.90 |
| ATR | 3.8989 |
| Shares Float | 49.00M |
| Short Float | 11.15% |
| Short Ratio | 9.67 |
| Volatility | 1.15 |
| Rel Volume | 0.26 |
Performance History
| Week | +0.07% |
| Month | +21.93% |
| Quarter | +28.01% |
| 6 Months | +21.72% |
| YTD | +22.41% |
| Year | +64.59% |
| 3 Years | +176.28% |
| 10 Years | +558.35% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $123.44 | 1,329,649 |
| 2026-06-22 | $123.42 | 2,094,200 |
| 2026-06-18 | $123.43 | 4,603,600 |
| 2026-06-17 | $123.36 | 4,844,300 |
| 2026-06-16 | $123.39 | 2,257,600 |
| 2026-06-15 | $123.35 | 2,969,500 |
| 2026-06-12 | $123.25 | 7,237,300 |
| 2026-06-11 | $123.45 | 6,582,100 |
| 2026-06-10 | $123.35 | 6,272,900 |
| 2026-06-09 | $123.25 | 51,699,500 |
| 2026-06-08 | $88.49 | 1,225,700 |
| 2026-06-05 | $90.95 | 716,000 |
| 2026-06-04 | $94.02 | 937,900 |
| 2026-06-03 | $90.18 | 1,475,600 |
| 2026-06-02 | $91.35 | 1,723,100 |
| 2026-06-01 | $93.01 | 2,945,000 |
| 2026-05-29 | $110.39 | 1,169,600 |
| 2026-05-28 | $109.27 | 723,100 |
| 2026-05-27 | $107.38 | 631,600 |
| 2026-05-26 | $104.95 | 425,600 |
About Nuvalent, Inc.
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Hereâs What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)
Insider Monkey âĸ 2026-06-16T18:45:52Z
The biotech market is rebounding. So where are the executive jobs?
Pharma Voice âĸ 2026-06-15T08:38:12Z
MarketBeat Week in Review â 06/08 - 06/12
MarketBeat âĸ 2026-06-13T11:00:00Z
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
MarketBeat âĸ 2026-06-11T16:25:00Z
Nike downgraded, Oscar Health upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-10T13:42:21Z
GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts
Proactive âĸ 2026-06-10T12:21:00Z
Here Are Wednesdayâs Top Wall Street Analyst Research Calls: BILL Holdings, Cava Group, Entergy, GlobalFoundries, Hess Midstream, Nike, Pfizer, SharkNinja, STMicroelectronics, and More
24/7 Wall St. âĸ 2026-06-10T11:59:02Z
GSK Buys Nuvalent To Deepen Oncology Focus And Future Lung Cancer Revenue
Simply Wall St. âĸ 2026-06-10T05:10:45Z
New GSK CEOâs Cancer Deal Signals Bigger Ambitions
The Wall Street Journal âĸ 2026-06-10T01:00:00Z
GSKâs US$10.6b Nuvalent Deal Highlights Lung Cancer And Valuation Upside
Simply Wall St. âĸ 2026-06-10T00:17:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $414,307,000 | $280,368,000 | $149,492,000 | $86,108,000 |
| Other Income Expense | $-55,220,000 | $-17,940,000 | - | $4,254,000 |
| Other Non Operating Income Expenses | $-55,220,000 | $-17,940,000 | - | $4,254,000 |
| Net Non Operating Interest Income Expense | $44,735,000 | $38,316,000 | $23,273,000 | $4,254,000 |
| Operating Expense | $414,307,000 | $280,368,000 | $149,492,000 | $86,108,000 |
| General And Administrative Expense | $107,337,000 | $62,594,000 | $36,249,000 | $22,377,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-425,377,000 | $-260,756,000 | $-126,219,000 | $-81,854,000 |
| Net Interest Income | $44,735,000 | $38,316,000 | $23,273,000 | $4,254,000 |
| Interest Income | $44,735,000 | $38,316,000 | $23,273,000 | $4,254,000 |
| Normalized Income | $-425,377,000 | $-260,756,000 | $-126,219,000 | $-81,854,000 |
| Net Income From Continuing And Discontinued Operation | $-425,377,000 | $-260,756,000 | $-126,219,000 | $-81,854,000 |
| Total Operating Income As Reported | $-414,307,000 | $-280,368,000 | $-149,492,000 | $-86,108,000 |
| Net Income Common Stockholders | $-425,377,000 | $-260,756,000 | $-126,219,000 | $-81,854,000 |
| Net Income | $-425,377,000 | $-260,756,000 | $-126,219,000 | $-81,854,000 |
| Net Income Including Noncontrolling Interests | $-425,377,000 | $-260,756,000 | $-126,219,000 | $-81,854,000 |
| Net Income Continuous Operations | $-425,377,000 | $-260,756,000 | $-126,219,000 | $-81,854,000 |
| Pretax Income | $-424,792,000 | $-259,992,000 | $-126,219,000 | $-81,854,000 |
| Interest Income Non Operating | $44,735,000 | $38,316,000 | $23,273,000 | $4,254,000 |
| Operating Income | $-414,307,000 | $-280,368,000 | $-149,492,000 | $-86,108,000 |
| Per Share | ||||
| Diluted EPS | $-5.85 | $-3.93 | $-2.17 | $-1.65 |
| Basic EPS | $-5.85 | $-3.93 | $-2.17 | $-1.65 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-414,307,000 | $-280,368,000 | $-149,492,000 | $-86,108,000 |
| EBITDA (Bullshit earnings) | $-414,307,000 | $-280,368,000 | $-149,492,000 | $-86,108,000 |
| EBIT | $-414,307,000 | $-280,368,000 | $-149,492,000 | $-86,108,000 |
| Diluted Average Shares | $72,686,749 | $66,408,807 | $58,223,339 | $49,668,864 |
| Basic Average Shares | $72,686,749 | $66,408,807 | $58,223,339 | $49,668,864 |
| Diluted NI Availto Com Stockholders | $-425,377,000 | $-260,756,000 | $-126,219,000 | $-81,854,000 |
| Tax Provision | $585,000 | $764,000 | $0 | $0 |
| Research And Development | $306,970,000 | $217,774,000 | $113,243,000 | $63,731,000 |
| Selling General And Administration | $107,337,000 | $62,594,000 | $36,249,000 | $22,377,000 |
| Other Gand A | $15,033,000 | $10,854,000 | $6,423,000 | $22,377,000 |
| Insurance And Claims | $28,626,000 | $9,634,000 | $6,738,000 | $5,462,000 |
| Salaries And Wages | $63,678,000 | $42,106,000 | $23,088,000 | $12,316,000 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,248,339,000 | $1,069,792,000 | $700,561,000 | $462,978,000 |
| Total Assets | $1,412,705,000 | $1,141,752,000 | $732,384,000 | $482,459,000 |
| Total Non Current Assets | $20,279,000 | $9,304,000 | $5,896,000 | $4,468,000 |
| Other Non Current Assets | $20,279,000 | $9,304,000 | $5,896,000 | $4,468,000 |
| Current Assets | $1,392,426,000 | $1,132,448,000 | $726,488,000 | $477,991,000 |
| Other Current Assets | $20,474,000 | $14,146,000 | $6,583,000 | $5,828,000 |
| Cash Cash Equivalents And Short Term Investments | $1,371,952,000 | $1,118,302,000 | $719,905,000 | $472,163,000 |
| Cash And Cash Equivalents | $261,745,000 | $145,691,000 | $335,387,000 | $241,806,000 |
| Prepaid Assets | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $164,366,000 | $71,960,000 | $31,823,000 | $19,481,000 |
| Total Non Current Liabilities Net Minority Interest | $73,195,000 | $17,940,000 | $0 | $0 |
| Other Non Current Liabilities | $35,000 | - | - | - |
| Tradeand Other Payables Non Current | $0 | $0 | $0 | - |
| Current Liabilities | $91,171,000 | $54,020,000 | $31,823,000 | $19,481,000 |
| Payables And Accrued Expenses | $74,236,000 | $43,568,000 | $24,497,000 | $14,629,000 |
| Payables | $30,158,000 | $5,225,000 | $9,274,000 | $7,195,000 |
| Accounts Payable | $30,158,000 | $5,225,000 | $9,274,000 | $7,195,000 |
| Equity | ||||
| Common Stock Equity | $1,248,339,000 | $1,069,792,000 | $700,561,000 | $462,978,000 |
| Total Equity Gross Minority Interest | $1,248,339,000 | $1,069,792,000 | $700,561,000 | $462,978,000 |
| Stockholders Equity | $1,248,339,000 | $1,069,792,000 | $700,561,000 | $462,978,000 |
| Gains Losses Not Affecting Retained Earnings | $2,353,000 | $-59,000 | $31,000 | $-494,000 |
| Other Equity Adjustments | $2,353,000 | $-59,000 | $31,000 | $-494,000 |
| Retained Earnings | $-972,429,000 | $-547,052,000 | $-286,296,000 | $-160,077,000 |
| Other | ||||
| Ordinary Shares Number | $78,239,365 | $71,344,818 | $64,065,150 | $56,668,955 |
| Share Issued | $78,239,365 | $71,344,818 | $64,065,150 | $56,668,955 |
| Tangible Book Value | $1,248,339,000 | $1,069,792,000 | $700,561,000 | $462,978,000 |
| Invested Capital | $1,248,339,000 | $1,069,792,000 | $700,561,000 | $462,978,000 |
| Working Capital | $1,301,255,000 | $1,078,428,000 | $694,665,000 | $458,510,000 |
| Total Capitalization | $1,248,339,000 | $1,069,792,000 | $700,561,000 | $462,978,000 |
| Additional Paid In Capital | $2,218,407,000 | $1,616,895,000 | $986,819,000 | $623,543,000 |
| Capital Stock | $8,000 | $8,000 | $7,000 | $6,000 |
| Common Stock | $8,000 | $8,000 | $7,000 | $6,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Dueto Related Parties Non Current | $73,160,000 | $17,940,000 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $16,935,000 | $10,452,000 | $7,326,000 | $4,852,000 |
| Current Accrued Expenses | $44,078,000 | $38,343,000 | $15,223,000 | $7,434,000 |
| Other Short Term Investments | $1,110,207,000 | $972,611,000 | $384,518,000 | $230,357,000 |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-275,209,000 | $-185,064,000 | $-99,739,000 | $-64,971,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-275,209,000 | $-185,064,000 | $-99,739,000 | $-64,971,000 |
| Cash Flow From Continuing Operating Activities | $-275,209,000 | $-185,064,000 | $-99,739,000 | $-64,971,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-124,077,000 | $-573,514,000 | $-143,527,000 | $-10,665,000 |
| Cash Flow From Continuing Investing Activities | $-124,077,000 | $-573,514,000 | $-143,527,000 | $-10,665,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $515,722,000 | $569,987,000 | $338,480,000 | $250,470,000 |
| Financing Cash Flow | $515,340,000 | $568,882,000 | $336,847,000 | $248,916,000 |
| Cash Flow From Continuing Financing Activities | $515,340,000 | $568,882,000 | $336,847,000 | $248,916,000 |
| Net Other Financing Charges | $-382,000 | $-1,105,000 | $-1,633,000 | $-1,554,000 |
| Net Common Stock Issuance | $515,722,000 | $569,987,000 | $338,480,000 | $250,470,000 |
| Common Stock Issuance | $515,722,000 | $569,987,000 | $338,480,000 | $250,470,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $261,745,000 | $145,691,000 | $335,387,000 | $241,806,000 |
| Beginning Cash Position | $145,691,000 | $335,387,000 | $241,806,000 | $68,526,000 |
| Changes In Cash | $116,054,000 | $-189,696,000 | $93,581,000 | $173,280,000 |
| Net Investment Purchase And Sale | $-124,077,000 | $-573,514,000 | $-143,527,000 | $-10,665,000 |
| Sale Of Investment | $933,689,000 | $451,449,000 | $315,959,000 | $202,251,000 |
| Purchase Of Investment | $-1,057,766,000 | $-1,024,963,000 | $-459,486,000 | $-212,916,000 |
| Change In Working Capital | $19,208,000 | $11,842,000 | $11,026,000 | $6,931,000 |
| Change In Other Current Assets | $-10,508,000 | $-3,408,000 | $-1,428,000 | $-1,272,000 |
| Change In Payables And Accrued Expense | $36,058,000 | $22,813,000 | $11,810,000 | $9,694,000 |
| Change In Accrued Expense | $11,459,000 | $26,862,000 | $9,641,000 | $5,482,000 |
| Change In Payable | $24,599,000 | $-4,049,000 | $2,169,000 | $4,212,000 |
| Change In Account Payable | $24,599,000 | $-4,049,000 | $2,169,000 | $4,212,000 |
| Change In Prepaid Assets | $-6,342,000 | $-7,563,000 | $644,000 | $-1,491,000 |
| Other Non Cash Items | $44,458,000 | $3,271,000 | $-10,109,000 | $-373,000 |
| Stock Based Compensation | $86,502,000 | $60,579,000 | $25,563,000 | $10,325,000 |
| Net Income From Continuing Operations | $-425,377,000 | $-260,756,000 | $-126,219,000 | $-81,854,000 |
| Proceeds From Stock Option Exercised | - | - | $14,180,000 | $1,840,000 |
| Amortization Of Securities | - | - | $-10,109,000 | $-373,000 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-14